About Lyell Immunopharma
Lyell Immunopharma (NASDAQ:LYEL) focuses on pioneering treatments in the field of cancer immunotherapy, working tirelessly to develop innovative T cell therapies aimed at solid tumors. While it's solely listed on the NASDAQ market, Lyell Immunopharma's projects revolve around the convergence of cell engineering and its applications in combating cancer, striving to enhance the efficacy and durability of T cell therapies. The company's objectives are anchored in leveraging cutting-edge science to create a robust pipeline of transformative cancer treatments, with the ultimate aim of achieving long-lasting remissions for patients battling various forms of the disease. Their work is a testament to their commitment to revolutionizing cancer care through scientific discovery and therapeutic innovation.
Snapshot
Operations
Produtos e/ou serviços de Lyell Immunopharma
- Developing T-cell therapies aimed at solid tumors, utilizing unique reprogramming techniques to enhance efficacy.
- Collaborating on enhancing CAR-T therapies for improved persistence and potency in cancer treatment.
- Investigating the mechanisms of T-cell exhaustion to devise novel interventions and enhance immunotherapies.
- Pioneering the use of next-generation sequencing and machine learning to identify T-cell receptor repertoires for solid tumors.
- Focusing on the integration of synthetic biology to construct engineered T-cells with superior anti-tumor activity.
- Advancing techniques for the ex vivo expansion of tumor-infiltrating lymphocytes to boost their effectiveness in patient treatments.
equipe executiva do Lyell Immunopharma
- Dr. Richard D. Klausner M.D.Founder & Executive Chairman
- Dr. Lynn Seely M.D., Ph.D.Interim Principal Financial Officer, Principal Executive Officer, President, CEO & Director
- Mr. Stephen J. HillChief Operating Officer
- Prof. Stanley R. Riddell M.D.Founder & Scientific Advisor
- Dr. Crystal L. Mackall M.D.Founder & Scientific Advisor
- Nellie DilleryDirector of Accounting
- Dr. Gary K. Lee Ph.D.Chief Scientific Officer
- Mr. Mark A. Meltz J.D.General Counsel & Corporate Secretary
- Ms. Ann TomlinChief Human Resources Officer
- Mr. Bryan SelbySenior Vice President of Clinical Development Operations